Adipose tissue-derived stem cells (ASCs) are an attractive source of stem cells with regenerative properties that are similar to those of bone marrow stem cells. Here, we analyze the role of ASCs in reducing the progression of kidney fibrosis. Progressive renal fibrosis was achieved by unilateral clamping of the renal pedicle in mice for 1 h; after that, the kidney was reperfused immediately. Four hours after the surgery, 2 ´ 10 5 ASCs were intraperitoneally administered, and mice were followed for 24 h posttreatment and then at some other time interval for the next 6 weeks. Also, animals were treated with 2 ´ 10 5 ASCs at 6 weeks after reperfusion and sacrificed 4 weeks later to study their effect when interstitial fibrosis is already present. At 24 h after reperfusion, ASCtreated animals showed reduced renal dysfunction and enhanced regenerative tubular processes. Renal mRNA expression of IL-6 and TNF was decreased in ASC-treated animals, whereas IL-4, IL-10, and HO-1 expression increased despite a lack of ASCs in the kidneys as determined by SRY analysis. As expected, untreated kidneys shrank at 6 weeks, whereas the kidneys of ASC-treated animals remained normal in size, showed less collagen deposition, and decreased staining for FSP-1, type I collagen, and Hypoxyprobe. The renal protection seen in ASC-treated animals was followed by reduced serum levels of TNF-a, KC, RANTES, and IL-1a. Surprisingly, treatment with ASCs at 6 weeks, when animals already showed installed fibrosis, demonstrated amelioration of functional parameters, with less tissue fibrosis observed and reduced mRNA expression of type I collagen and vimentin. ASC therapy can improve functional parameters and reduce progression of renal fibrosis at early and later times after injury, mostly due to early modulation of the inflammatory response and to less hypoxia, thereby reducing the epithelial-mesenchymal transition.
INTRODUCTION
Despite all efforts to manage acute kidney injury (AKI) patients, this syndrome is still associated with high mortality and morbidity rates. Moreover, it has a high incidence and may affect approximately 7% of all hospitalized patients, with the mortality rate reaching near 50% of AKI patients in intensive care units (ICUs) (34, 40) . Among long-term AKI surviving patients (1-10 years), approximately 12.5% are dialysis dependent and 19-31% develop chronic kidney disease (CKD) (15). This scenario can be caused by incomplete repair of epithelial cells after AKI and persistent tubule-interstitial inflammation, leading to an increase in fibroblast proliferation and the activation of myofibroblasts and resulting in excessive deposition of extracellular matrix proteins in kidney (15, 31) . The epithelial-to-mesenchymal transition (EMT) has been suggested as one the main pathways in fibrosis development in the progression of AKI to CKD (24, 41) .
The EMT can be viewed as an adaptive response of epithelial cells after chronic stress/injury. Hypoxia, oxidative stress, and inflammation can produce and release several chemokines and cytokines that attract and direct the influx of inflammatory cells to the tubule-interstitial space. Infiltrating cells, in turn, activate and produce a mixture of soluble factors, including proinflammatory and profibrotic cytokines as well as matrix metallopeptidases (MMPs) (10,53), creating a hostile microenvironment for tubular epithelial and endothelial cells. In the early inflammatory phase of renal fibrosis, cytokines produced by infiltrating cells, such as interleukin-1 (IL-1), tumor necrosis factor-a (TNF-a), and interferon-g (IFN-g), profoundly potentiate tubular EMT triggered by transforming growth factor-b (TGF-b) through the upregulation of the TGF-b receptor (32). TGF-b is the main driving factor of fibrosis via the promotion of fibroblast proliferation, extracellular matrix synthesis, and the inhibition of collagenase in multiple organs, all hallmarks of EMT (28). TNF-a-dependent NF-kB activation also stabilizes the transcription factor Snail (potent EMT inducer) by blocking its ubiquitination, providing another molecular link between inflammation and EMT (2, 57) . The significance of renal inflammation in initiating and promoting EMT is also manifested by many observations that renal fibrosis is almost always preceded by and closely associated with chronic interstitial inflammation (19, 27) .
Adipose tissue-derived stem cells (ASCs) are easily isolated adult mesenchymal stem cells (65) that, when influenced by the extracellular milieu in vitro, have the capacity to differentiate into other cell types such as adipocytes, myocytes, osteoblasts, and neurons. They are known to secrete multiple growth factors and therefore have cytoprotective effects in various injury models (3, 33) . Gimble et al. have shown that ASCs delivered into an injured tissue may secrete cytokines and growth factors that stimulate recovery and clear toxic substances released into the local environmental lesion, promoting recovery of the surviving cells (14) . Several studies have demonstrated the ability of ASCs to downregulate immune system responses (11, 59) . They can suppress T-cell activation by inhibiting cyclin D2 expression (44), by inducing regulatory T cells (1, 16, 17) or by interfering with dendritic cells (1,23). Moreover, ASCs can act as antiapoptotic factors on target cells, increasing the recovery of renal function (45).
Recently, stem cell therapies have emerged as new strategies to halt the progression of chronic kidney diseases. Semedo et al. demonstrated that the administration of MSCs improved histological and functional parameters and reduced the fibrotic area in a severe model of renal ablation. The renal protective actions enabled by MSCs also attenuated chronic hypoxia, oxidative stress, and the production of inflammatory cytokines that lead to EMT and are all presented during CKD (7, 50, 51) . Several other studies have described the beneficial effects of ASC administration. ASC treatment leads to improved vascular supply (42, 45) , accelerated healing processes of skin wounds (39), periodontal tissue regeneration (54), cardiac wall regeneration (36), repair after myocardial infarction (49), and improvement of cellular function following stroke (25) . In this study, we hypothesize that ASCs can halt renal fibrosis progression in a specific animal model by the modulation of inflammatory events in different times. Moreover, ASC therapy also has the potential to improve renal function and tissue histology when renal scar was already installed.
MATERIALS AND METHODS

Isolation of Adipose Tissue-Derived Stem Cells (ASCs)
Mouse adipose tissues dissected from the inguinal area were isolated from male C57BL/6J mice and digested with 0.075% collagenase IA (Sigma Aldrich, St. Louis, MO, USA) at 37°C for 30 min. The cell suspension was filtered through 70-µm mesh (BD Biosciences, San Jose, CA, USA) to remove tissue debris. Collagenase was then inactivated with fetal calf serum (FCS), and the cell suspension was washed with phosphate-buffered saline (PBS) solution and centrifuged twice for 5 min at 260 ´ g. The cell pellet was then suspended in 0.84% NH 4 Cl to remove red blood cells. Cells were washed and centrifuged twice with PBS and cultured on plastic dishes (TPP, Trasadingen, Switzerland) in low-glucose Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen Corporation, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Emcare, Campinas, SP, Brazil), until the cells reached 70-80% confluence. Cells were detached with trypsin and cultured until the fifth passage in 4 weeks.
ASC Immunophenotyping
Briefly, a cell suspension (1 ´ 10 5 cells) of ASCs was incubated for 40 min in saturating concentrations of the antibodies CD34-fluorescein isothiocyanate (FITC), CD105-FITC, CD73-phycoerythrin (PE), CD45-peridinin chlorophyll protein complex (PerCP), and CD90-FITC and matched isotype controls (all antibodies were purchased from BD Biosciences Pharmingen, San Diego, CA, USA). After three washes, the cells were centrifuged at 200 ´ g for 5 min and ressuspended in ice-cold PBS. Cell fluorescence was evaluated using a flow cytometer (FACSCanto; Becton Dickinson, Franklin Lakes, NJ, USA).
ASC Differentiation Assay
ASCs were differentiated into adipocytes by treatment with low-glucose DMEM supplemented with 10% FBS, dexamethasone (1 µM), isobutylmethylxanthine (0.5 mM), insulin (10 µg/ml), and indomethacin (100 µM) for 14 days. Osteoblast differentiation was achieved with lowglucose DMEM supplemented with 10% FBS, dexamethasone (0.1 µM), ascorbic acid (0.2 mM), and b-glycerol phosphate (10 mM) for 28 days. All reagents were purchased from Sigma-Aldrich. These assays were stained with Oil Red and Von Kossa to visualize lipid vesicles and calcium deposits, respectively.
Animal Model
Female C57BL/6J mice, 8 weeks of age, were obtained from CEDEME (Federal University of São Paulo, São Paulo, Brazil) and subjected to unilateral renal ischemia, as described by . Mice underwent abdominal incisions, and their left renal pedicle was bluntly dissected. A microvascular clamp (Rocca, São Paulo, SP, Brazil) was placed on the left renal pedicle for 60 min. Animal temperature was maintained near 37°C. Animals were monitored and maintained for 24 h, 6 weeks, or 10 weeks before sacrifice. The animals groups was separated as follows: group 1 (n = 5), animals Sham sacrificed after 24 h; group 2 (n = 6), animals submitted to unilateral ischemia reperfusion (IR) and sacrificed 24 h later; group 3 (n = 6), animals submitted to unilateral IR treated with ASCs and sacrificed 24 h later; group 4 (n = 5), animals Sham sacrificed after 6 weeks; group 5 (n = 6), animals submitted to unilateral IR and sacrificed 6 weeks later; group 6 (n = 6), animals submitted to unilateral IR treated with ASCs and sacrificed 6 weeks later; group 7 (n = 5), animals Sham sacrificed after 10 weeks; group 8 (n = 6), animals submitted to unilateral IR and sacrificed 10 weeks later; group 9 (n = 6), animals submitted to unilateral IR treated with ASC and sacrificed 10 weeks later. Sham animals underwent the same surgical procedure without clamping of the renal artery. All experimental procedures were approved by the local research ethics committee (CEP process no. 0058/2010).
Cell Treatment
It used sex-mismatched cells for transplantation. After 4 h of surgery, female mice received male ASCs intraperitoneally and were sacrificed 24 h or 6 weeks after surgery. Another group received the same ASC treatment 6 weeks after surgery and were sacrificed at 10th week posttreatment. Cells (2 ´ 10 5 ) were administered to each animal.
Assessment of Renal Function
Blood was collected from inferior vena cava for serum creatinine and urea measurements. Serum creatinine was measured by Jaffé's modified method. Serum urea was measured using a Labtest Kit (Labtest, Lagoa Santa, MG, Brazil).
Morphology
Kidneys obtained 6 and 10 weeks postischemia were analyzed by Masson and Picrosirius Red staining. For histological examinations, kidneys were fixed with 10% buffered formaldehyde for 24 h, washed with 70% ethanol for 24 h, and then embedded in paraffin. Sections were cut to a thickness of 4 µm. To evaluate the extent of renal interstitial expansion, the fraction of the renal cortex that stained positively for extracellular matrix components (collagen) was quantitatively evaluated in Masson-stained sections by a point-counting technique in consecutive microscopic fields at a final magnification of 100´ under a 176-point grid. Picrosirius Red staining was measured at a magnification of 20´ using the NIS Elements program of Nikon microscopy with at least 20 consecutive fields. Acute tubular necrosis (ATN) was measured in kidney sections stained with hematoxylin-eosin by a blinded reviewer. The extension of tubular necrosis (ATN) morphology and patterns of regeneration in the kidney was examined by blinded morphometric assessment using a computer-assisted image system with an Olympus BX40F-3 microscope (Olympus Optical Company, Tokyo, Japan) and the software program KS300 program (zeiss, Göttingen, Germany). The results were expressed as a ratio of the injured area related to total area (1,458,467 mm 2 ). Twenty-five random fields were counted at an original magnification of 835´, almost covering the whole kidney, corresponding to an area of 36,461,675 mm 2 , for each animal, per lamina. For morphometric analyses, ATN and regeneration were analyzed at 24 h after reperfusion. Tubular necrosis pattern included loss of cytoplasmatic and nuclear membranes integrity, loss of brush border, vacuolization of tubular epithelial cells, and presence of intratubular debris. Tubular regeneration or repair was characterized by attenuated epithelium enclosing dilated lumens filled with proteinaceous fluid or granular material.
Real-Time PCR
Kidney samples were quickly frozen in liquid nitrogen. Total RNA was isolated using the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), and RNA concentrations were determined by Nanodrop. First-strand cDNAs were synthesized using the MML-V reverse transcriptase (Promega, Madison, WI, USA). Reverse transcriptase polymerase chain reaction (RT-PCR) was performed using TaqMan (Applied Biosystem, USA) for the following molecules: collagen-1 (Col-1) (00801666_g1), connective tissue growth factor (CTGF) (Mm01192931_g1), IL-1b (Mm01336189_m1), IL-4 (Mm00445259_m1), IL-6 (00561420_m1), IL-10 (Mm00439616_m1), inducible nitric oxide synthase (iNOS) (Mm01309902_m1), hemeoxygenase-1 (HO-1) (Mm00516004_m1), hypoxanthine phosphoribosyltransferase (HPRT) (Mm00446968_m1), sex-determining region Y (SRY) (Mm00441712_s1), TNF-a (Mm00443258_m1), vascular endothelial growth factor (VEGF) (Mm01281449-m1), and vimentin (00449201_m1). Cycling conditions were as follows: 10 min at 95°C followed by 45 cycles of 20 sec at 95°C, 20 at 58°C, and 20 at 72°C. RT-PCR was performed using the SYBR Green real-time PCR assay (Applied Biosystem, USA) for the following molecules: HPRT (sense) 5¢-CTC ATG GAC TGA TTA TGG ACA GGA C-3¢, (antisense) 5¢-GCA GGT CAG CAA AGA ACT TAT AGC C-3¢; bone morphogenetic protein-7 (BMP-7) (sense) 5¢-AGA ATT CTT CCA CCC TCG ATA CC-3¢, (antisense) 5¢-TCC TTA TAG ATC CTG AAT TCG GCT-3¢; and TGF-b (sense) 5¢-AAC TAT TGC TTC AGC TCC ACA GAG A-3¢, (antisense) 5¢-GTT GGC ATG GTA GCC CTT G-3¢. Sequence Detection Software 1.9 (SDS) was used for analysis, and mRNA expression was normalized to HPRT abundance. The values are expressed relative to a reference (the calibrator) from the sham-operated samples. The Ct (threshold cycle) for the target gene and the Ct for the internal control were determined for each sample. Samples were run in triplicate. The relative expression of mRNA was calculated by 2 -DDCt . All the experimental samples are expressed as an n-fold difference relative to the calibrator.
Bio-Plex
A Bio-Plex mouse 23-Plex cytokine assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to test samples for the presence of 23 cytokines. The assay was read on the Bio-Plex suspension array system, and the data were analyzed using Bio-Plex Manager software version 4.0. Standard curves ranged from 32,000 to 1.95 pg/ml.
Immunohistochemistry
Collagen-I (diluted 1:200; COL-1, AbCAM, Cambridge, MA, USA), fibroblast specific protein-1 (FSP-1) (diluted 1:400, S100A4, DAKO), proliferating cell nuclear antigen (PCNA) (diluted 1:300; clone PC10, DAKO), and Hypoxyprobe (diluted 1:500; 121 Middlesex Turnpike, Burlington, MA USA) staining were performed in paraffinembedded sections. Previously, the slides were deparaffinized, rehydrated, and submitted to Tris-EDTA (pH 9) antigen retrieval solution treatment at 95°C. For Hypoxyprobe, the antigen retrieval solution used was citrate buffer (10 mM) at 55°C. The endogenous peroxidase activity was blocked with 3% hydrogen peroxide, and sections were blocked with protein block solution (DAKO, Carpinteria, CA, USA). Slides were then incubated with primary antibody or negative control reagent, followed by incubation with the labeled polymer Envision (DAKO), using two sequential 30-min incubations at room temperature. Staining was completed by a 1-to 3-min incubation with 3,3¢-diaminobenzidine (DAB)+ substrate-chromogen, which results in a brown-colored precipitate at the antigen site. Hematoxylin counterstaining was also completed. To analyze tissue hypoxia, we administered Hypoxyprobe TM -1 (pimonidazole HCl) solution at a dosage of 60 mg/kg body weight (IP) approximately 25 min before sacrifice. Following injection, Hypoxyprobe TM -1 (HPI, Inc., Burlington, MA, USA) is distributed to all tissues but forms adducts with thiol-containing proteins only in those cells that have oxygen partial pressure lower than 10 mmHg (pO 2 ≤ 10 mmHg) at 37°C.
Statistical Analysis
Data were expressed as the mean ± SD. Differences between the groups were evaluated for statistical significance using ANOVA followed by the Bonferroni test and Student's t test. Differences were considered significant at p < 0.05.
RESULTS
Isolation of ASCs and Characterization
ASCs were characterized by immunephenotype assays using several cell surface markers described in the literature (65). CD34, CD73, CD105, and CD45 were assessed. Expression of CD73 was 24.9% ± 40.9%, CD105 71.2% ± 19.7%, CD34 6.0% ± 3.8%, CD45 6.9% ± 1.9%, and CD90 81.7% ± 1.5%. These results were expected based on the already described ASC immunephenotype profile (18, 35, 65) . First passage cells were submitted to parallel adipocyte and osteocyte differentiation assays. Under supplemented specific medium, cells differentiated to adipocytes were identified by the visualization of lipid droplets inside cells by Oil Red staining. Osteocyte differentiation was also performed, and after 28 days under osteocyte medium, calcium deposits were observed via Von Kossa staining (data not shown).
ASC Treatment Leads to In Situ and Systemic Immune Modulation
In this model, severe ischemia and reperfusion is achieved in only one kidney. However, due to long ischemic time 
FACING PAGE
(1 h), kidney functional parameter was altered. Although no difference was found in creatinine levels (data not shown), urea serum levels were increased in animals subjected to this severe ischemia when compared to sham animals, but ASC treatment presented less renal dysfunction (Fig. 1A) . These findings correlated with acute tubular necrosis (ATN) analyses as the kidney submitted to ischemia had a higher area of necrosis after 24 h (Fig. 1B) , whereas ATN was decreased in ASC-treated animals. Moreover, regeneration patterns were higher in ASC-treated animals (Fig. 1C, E) as confirmed by PCNA staining (Fig. 1F-H) .
Inflammation has an important role in kidney ischemiareperfusion outcomes (8, 21, 22) . In addition, it is known that ASCs leads to immune modulation. Therefore, we analyzed mRNA expression of several cytokines after ASC treatment. IL-6 mRNA expression was reduced in the kidney tissue of ASC-treated animals (Fig. 1I ). TNF-a and IL-1b mRNA expression were also quantified, but no statistical differences were observed (Fig. 1J, K) , although ASC-treated animals had reduced expression. Surprisingly, anti-inflammatory mRNA cytokines IL-4 and IL-10 were augmented in the kidney tissue of ASCtreated animals (Fig. 1L, M) .
Systemically, we again found the same immunomodulatory pattern demonstrated in kidney tissue. Serum proinflammatory cytokines, such as IL-1a, IL-1b, IL-12 (p70), and keratinocyte-derived chemokine (KC), were decreased in ASC-treated group (Table 1) . IL-6 and IL-13 levels were also assessed, but no differences were observed (Table 1) . Levels of cytokine regulated upon activation normal T cell expressed and presumably secreted (RANTES or CCL5) were also reduced in ASC-treated animals ( Table 1 ). In this multiplex assay, Granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), IL-12 (p40), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1b (MIP-1b), and TNF-a levels did not differ between ASCtreated animals and untreated animals. Moreover, IL-2, IL-3, IL-4, IL-10, IL-17, MIP-1a, and IFN-g were not detected with this assay.
To track ASCs within kidneys after treatment, SRY mRNA expression was amplified by real-time PCR (Fig. 1N ). We did not detect SRY mRNA intensities, indicating the absence of these cells within the tissue at this time point.
Halting Fibrosis Progression by Downregulating Inflammation After Severe Ischemia
In this model of severe ischemia and reperfusion injury, it was observed that the kidney submitted to ischemia was shrunken after 6 weeks when compared to the contralateral kidney in untreated animals. Surprisingly, the ischemic kidneys of ASC-treated animals were not reduced in size ( Fig. 2A) . Despite it, creatinine and urea levels did not change with ASC treatment, probably due to the presence of the contralateral kidney, which can gradually compensate for the injured kidney's functional loss (Fig. 2B, C) . These shrunken kidneys showed higher areas of fibrosis, as demonstrated by Masson Trichrome and Picrosirius Red stainings ( Fig. 2D-F) . No relevant fibrosis was seen in the sham-operated group.
We also quantified mRNA expression of some profibrotic molecules to strengthen our quantification of collagen deposition data. Type 1 collagen (Col-1), vimentin, and connective tissue growth factor (CTGF) expression were assessed in renal tissue after 6 weeks. Again, reduced mRNA expression of those markers was observed in the kidney tissue of ASC-treated animals (Fig. 3A-C) . Furthermore, to confirm these results, protein analyses were completed using immunohistochemistry assays for fibroblast-specific protein 1 (FSP-1) and Col-1. As seen in Figure 3D , there is more pronounced staining of FSP-1 and Col-1 in the group of untreated animals, indicating 
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an enlarged population of fibroblasts with greater extracellular matrix protein deposition.
Systemic Immunomodulation After ASC Treatment
As early as 24 h after severe ischemia and reperfusion injury, we observed an important modulation of the inflammatory response in ASC-treated animals. As this reduced inflammation at the early time point could be implicated in the progression of fibrosis, we further investigated the inflammatory patterns inside the kidney and at 24 h and 6 weeks after therapy. Moreover, via real-time PCR some protective and angiogenic molecules related to tissue repair was quantified. At 6 weeks posttreatment, the expression of renal proinflammatory cytokines, such as TNF-a and IL-6, was still reduced in animals subjected to severe ischemia (Fig. 4A, B) and treated with ASCs. In addition, hemeoxygenase-1 (HO-1) levels and BMP-7/TGF-b ratios were increased in those animals as compared to untreated animals (Fig. 4C, D) . ASC therapy also led to systemic immunomodulation, as serum cytokine levels were reduced in ASCtreated animals. IL-1a, TNF-a, KC, and RANTES levels were also significantly reduced in those animals when compared to untreated animals ( Fig. 4E-H) . Levels of IL-6 did not differ between these two groups, although a tendency toward a reduction in this cytokine was observed in ASCtreated animals (Fig. 4I) .
Protective Effects of ASC Against Chronic Hypoxia
Chronic hypoxia due to the rarefaction of capillaries is one possible theory to explain the continuous progression of renal fibrosis, as low oxygen tension can be a major factor for the promotion of EMT. Therefore, we analyzed whether tissue hypoxia was reduced in renal tissue by using a probe that detects lower areas of pO 2 . Kidneys of ASC-treated animals demonstrated lower areas of hypoxia as compared to untreated animals (Fig. 4J) . Moreover, the expression of iNOS was augmented in kidney tissue in ASC-treated animals, and there were a tendency toward an augmentation in VEGF expression ( Fig. 4K, L) . The higher expression of these molecules in ASC-treated animals can be due to an improvement in kidney vascularization due to ASC angiogenic properties.
Reversion of Renal Fibrosis by ASC Treatment
The role of ASC in reverting established renal fibrosis was tested. ASCs were administrated at 6 weeks after ischemia, and animals were followed up to the 10th week postischemia treatment. Surprisingly, the kidneys of ASCtreated animals showed reduced areas of fibrosis, as analyzed by Picrosirius Red staining (Fig. 5A, B) . Moreover, a functional amelioration of kidney was also observed and correlated with these reduced areas of fibrosis (Fig. 5C, D) . Confirming these data, mRNA expression of vimentin was reduced in ASC-treated animals when compared to the untreated group (Fig. 6A ). Type I collagen mRNA expression was also decreased in ASC-treated animals, but no significant difference was observed (Fig. 6B) . In addition, the immunohistochemistry assay for type I collagen and FSP-1 correlated with gene analysis studies (Fig. 6C) . Furthermore, the mRNA expression levels of IL-10 and BMP-7 were increased after ASC treatment (Fig. 6D, E) . Again, despite the positive effect achieved, ASCs could not be visualized in kidney tissue, as analyzed by SRY mRNA expression ( Fig. 6F) .
DISCUSSION
In 2002, ASCs were first described by zuk et al. (64), after which, the number of ASC studies increased exponentially. The regenerative properties of the ASCs are of great interest in the treatment of many diseases (63). This is particularly true for fibroproliferative diseases where tissue destruction caused by extracellular matrix deposition leads to organ function loss. Of further importance is the consideration that the interaction of the epithelial tubular cell and extracellular matrix is crucial to determine kidney function.
CKD is emerging as a worldwide health problem. The possible therapies to end-stage renal failure include dialysis and transplantation; however, these treatments do not always meet patient needs (30) . Several comorbitities may cause CKD, but one aspect is continually overlooked: persistent inflammation after AKI events (47, 58) . Inflammation triggers fibrosis progression in the kidney and leads to the transformation of an epithelial cell to a myofibroblast, the so-called EMT (24). Whether EMT occurs in vivo is not known, the role of inflammation on fibrosis scar formation is not questioned. Despite functional amelioration after AKI, residual inflammation may contribute to epithelial injury leading to fibrosis. In this model of severe unilateral ischemia, the remaining inflammation causes kidneys to shrink due to fibrosis scar formation. It is noteworthy to emphasize that no ideal mouse model for CKD exist that can reproduce all features see in humans. However, this model allows us to study hypoxia, inflammation, and ultimately its consequence, renal fibrosis.
Here, we propose that ASCs may inhibit EMT by decreasing inflammation. At 24 h posttreatment, animals had better outcomes that were functionally correlated with downregulation of inflammation. The consequences of this immunomodulation are reflected at 6 weeks posttreatment when lower fibrosis areas are seen.
Our group has shown that a single episode of severe unilateral renal ischemia leads to inflammation that results in the development of fibrosis (12). The main mechanism of action for adult stem cells is immunoregulation (23, 55) . This occurs predominantly through a paracrine effect mediated by ASCs called touch and go, where these cells are thought to migrate to the injury area, to secrete immune factors and later, to leave the tissue, and/or to die. This might explain why ASCs were not seen in the kidney tissues of ASC-treated animals. At early time, we found that ASC therapy modulates inflammation, with decreased expression of renal and systemic levels of Th1 cytokines (IL-1b, IL-6, and TNF-a) and increased protective renal Th2 cytokine (IL-4 and IL-10) expression. This modulation reflected in an improvement in histological and functional organ parameters.
It was believed that patients who survived an initial AKI would have a complete return of renal function. Today, however, data from animal models and from clinical studies have put on check the long-term consequences of AKI (4,12,43). In our model, we observed a long-term effect of treatment with ASCs, where the initial immunomodulation was still persistent with enhanced expression of protective factors such as HO-1 and BMP-7. BMP-7 is a competitor of TGF-b receptor signaling. By calculating the ratio of BMP-7 and TGF-b, we found a protective effect of ASC administration, where the expression of BMP-7 was higher than TGF-b on treated animals. TGF-b is seen as the most important factor to induce fibrosis through activation of resident fibroblasts and by inducing EMT. These findings correlate to the quantification of fibrosis area found in animals after treatment, to a decreased expression of profibrotic factors (vimentin and type 1 collagen), to a decrease in fibroblasts infiltration (FSP-1-positive cells), and to a lower tissue collagen deposition. We can assume that early modulation of inflammation and TGF-b signaling pathway resulted in less fibrosis.
HO-1 is a protective gene involved in heme degradation, resulting in end products with anti-inflammatory, antioxidant, and antiapoptotic actions (5). Its upregulation correlates the cytoprotection found after treatment with ASCs. This decrease in inflammation seen by both the reduction of inflammatory factors and increase of protective factors is closely linked to less formation of fibrosis, since inflammation is one of the factors that induce EMT. Upregulation of HO-1 was already demonstrated to inhibit EMT (26, 52) in animal models where fibrosis development was modulated (12, 56) .
Hypoxia may also induce EMT (62). Among CKD progression theories, chronic hypoxia can trigger fibrosis in part due to vessels rarefaction. Here, we observed that ASC therapy may prevent the capillary loss. By using a probe that detects lower areas of pO 2 , a Hypoxyprobe, we found that hypoxic areas were reduced in ASC-treated animals as compared to controls. This might be due to an increased expression of both HO-1 and VEGF molecules. With the breakdown of heme by HO-1, biliverdin and carbon monoxide are released, which might be responsible for an increase in microcirculation and vasodilatation (5). In some conditions, iNOS expression is associated with inflammation (production of nitrogen reactive species). However, the production of NO by iNOS can also be associated with vasodilatation that ultimately decreases hypoxic areas, while it has angiogenic actions by positively modulating VEGF expression (6, 29, 37) . VEGF is a key factor for vessel growth and normal glomerular and vascular development (48). The higher expression of these molecules in ASC-treated animals illustrates the angiogenic characteristics of stem cells with consequent improvement in vascularization and in reduction of chronic hypoxia.
Although no ideal experimental model of CKD exists, we believe that the use of this severe ischemia model allows us to study the consequences of sustained inflammation and permits us to treat in a specific point and later access the improvement. For this purpose, we administrated the ASC 6 weeks after reperfusion, since at this point, our previous data together with corroborating literature show us the presence of interstitial fibrosis (4,12). Following the administration of the stem cells, we analyzed the results after 4 weeks. The results were startling. We found a higher mRNA expression of protective factors (IL-10 and BMP-7) and a lower expression of profibrotic factors, which were followed by less fibrosis quantified by histological and protein analysis.
Several studies already showed the possibility of fibrotic regression (13, 38, 46) . Inhibitors of angiotensin play an important role in the progression and potential regression of glomerulosclerosis (9,20,61). VEGF-A treatment also resulted in less injury and enhanced endothelial cell proliferation and capillary repair in models of acute glomerulonephritis or thrombotic microangiopathy (48) and ameliorated development of glomerulosclerosis and tubuleinterstitial fibrosis. Treatment with BMP-7 can reverse TGF-induced renal fibrosis in mice and repair severely damaged renal tubular epithelial cells, in association with reversal of chronic renal injury (60). So here, we present the possibility of a fibrotic regression with ASC treatment. We believe that the decrease of fibrosis is the result of a series of factors resulting from stem cells' biological properties. EMT inducers are activated in an inflammatory microenvironment, in which both TGF-b and hypoxia can induce the expression of specific transcription factors. The modulation of inflammation together with the increased expression of protective antifibrotic, angiogenic factors would lead to a blockade of EMT, where cells returned to epithelial and endothelial characteristics, through a continuous bidirectional event.
In summary, we propose that systemic ASC treatment halts and even reverses fibrosis instigated by a severe ischemia via the downregulation of inflammation and hypoxia.
